May 2025, Vol 2, No 5

As May is widely recognized as Skin Cancer Awareness Month, the team here at ImPACT would like to take this time to remind our readers about the very important intersection between military service and melanoma. Read More ›

The Nurses Organization of Veterans Affairs (NOVA) is a nationwide, nonprofit professional organization whose members are nurses, including advanced practice nurses (APNs), registered nurses (RNs), and licensed practical nurses (LPNs), who are currently working for the Department of Veterans Affairs (VA) or retired. Read More ›

Officials with the FDA have approved chenodiol (Ctexli; Mirum) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults, making it the first FDA-approved therapy to address this rare lipid storage disease. Read More ›

The FDA has approved a hormone-free, copper intrauterine device (IUD; Miudella; Sebela Pharmaceuticals) for the prevention of pregnancy in people of reproductive potential for up to 3 years, making it the first hormone-free IUD to be FDA approved in more than 40 years, according to a press release. Read More ›

Officials with the FDA have approved the allergy immunotherapy tablet Odactra (ALK) for use in young children with house dust mite allergy-induced allergic rhinitis, with or without conjunctivitis, in children aged 5 through 11 years, in addition to patients aged 12 through 65 years. Read More ›

GSK’s meningococcal groups A, B, C, W, and Y vaccine (Penmenvy) has been approved by the FDA for use in individuals aged 10 through 25 years. Read More ›

The FDA has approved the twice-daily oral capsule iptacopan (Fabhalta; Novartis) for the treatment of adults with complement 3 glomerulopathy (C3G) to reduce proteinuria. Read More ›

Officials with the FDA have granted traditional approval to pembrolizumab (Keytruda; Merck) with trastuzumab- (Herceptin; Genentech), fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥1. Read More ›

Cabozantinib (Cabometyx; Exelixis, Inc) has been approved by the FDA for use in patients aged >12 years who had previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET). Read More ›

On March 28, 2025, the FDA expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto; Novartis) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and who are considered appropriate to delay taxane-based chemotherapy. Read More ›